Strategic financing Recent $50M financing and FDA nod for Furoscix auto-injector present near-term opportunities to align with MannKind's infusion and device-enabled therapies, enabling co-marketing or co-development discussions with payer and provider networks.

Commercial momentum TTM revenue around $360M with ongoing commercialization in cardiometabolic and orphan lung diseases signals a ready market for expanded access programs, formulary negotiations, and regional sales expansions.

Inhaled pipeline Development of inhaled dry powder ralinepag and FDA-approved Technosphere Afrezza platform creates cross-sell opportunities for respiratory and diabetes care channels, as well as potential device integration with digital health partners.

Diabetes focus Active engagement at ADA sessions and data dissemination around Afrezza across pediatric, AID systems, and gestational diabetes indicates partnership avenues with endocrinology clinics, hospitals, and glucose-monitoring ecosystems.

Manufacturing footprint Danbury facility expansion and established manufacturing solutions point to capability for scale-up, contract manufacturing opportunities, and strategic alliances with mid- to large-scale healthcare distributors.